AMICUS THERAPEUTICS, INC. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Amicus Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • Amicus Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 404 %, a 22.4% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 404 -116 -22.4% Sep 30, 2024
Q2 2024 441 -79 -15.2% Jun 30, 2024
Q1 2024 459 -2.58 -0.56% Mar 31, 2024
Q4 2023 486 +120 +32.7% Dec 31, 2023
Q3 2023 520 +234 +81.7% Sep 30, 2023
Q2 2023 520 +302 +138% Jun 30, 2023
Q1 2023 461 +256 +124% Mar 31, 2023
Q4 2022 366 +165 +82% Dec 31, 2022
Q3 2022 286 +81.4 +39.7% Sep 30, 2022
Q2 2022 218 +2.53 +1.17% Jun 30, 2022
Q1 2022 206 +35.1 +20.6% Mar 31, 2022
Q4 2021 201 +65.6 +48.4% Dec 31, 2021
Q3 2021 205 +101 +96.2% Sep 30, 2021
Q2 2021 216 +138 +179% Jun 30, 2021
Q1 2021 171 +104 +154% Mar 31, 2021
Q4 2020 136 +71 +110% Dec 31, 2020
Q3 2020 104 +31.8 +43.8% Sep 30, 2020
Q2 2020 77.4 -5.99 -7.18% Jun 30, 2020
Q1 2020 67.2 -15 -18.2% Mar 31, 2020
Q4 2019 64.5 -16.5 -20.3% Dec 31, 2019
Q3 2019 72.7 +1.54 +2.17% Sep 30, 2019
Q2 2019 83.4 Jun 30, 2019
Q1 2019 82.1 Mar 31, 2019
Q4 2018 80.9 Dec 31, 2018
Q3 2018 71.1 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.